Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study
The DEPICT-2 trial (NCT02460978) evaluated the efficacy and safety of dapagliflozin (DAPA) as add-on to adjustable insulin (INS) in patients (pts) with inadequately controlled T1D (A1c 7.5-10.5%) over 24 weeks. This phase 3 study randomized pts 1:1:1 to DAPA 5 mg (n=271), 10 mg (n=270) or placebo (P...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 67; no. Supplement_1 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.07.2018
|
Online Access | Get full text |
Cover
Loading…
Abstract | The DEPICT-2 trial (NCT02460978) evaluated the efficacy and safety of dapagliflozin (DAPA) as add-on to adjustable insulin (INS) in patients (pts) with inadequately controlled T1D (A1c 7.5-10.5%) over 24 weeks. This phase 3 study randomized pts 1:1:1 to DAPA 5 mg (n=271), 10 mg (n=270) or placebo (PBO; n=272) plus INS. INS dose could be adjusted by the investigator according to self-monitored blood glucose readings, local guidance and individual circumstances. At Week 24, DAPA 5 and 10 mg significantly decreased A1c (0.37% and 0.42% reductions in the DAPA 5 mg and 10 mg groups respectively), total daily insulin dose (TDD), and body weight (Table). As measured by masked continuous glucose monitoring (CGM), mean interstitial glucose, mean amplitude of glucose excursion (MAGE) and mean percent of readings within target glycemic range (>70-≤180 mg/dL) vs. PBO were improved. There was an increase in pts who reduced their A1c by ≥0.5% without severe hypoglycemia (odds ratios [95% CI]: 2.71 [1.81, 4.06] and 3.07 [2.05, 4.60] for DAPA 5 and 10 mg respectively). Hypoglycemic events, including severe hypoglycemia were balanced between treatment groups. There were more adjudicated definite diabetic ketoacidosis (DKA) events on DAPA.
In conclusion, DAPA vs. PBO as add-on to INS in pts with T1D was well tolerated, improved glycemic control and decreased variability without increasing hypoglycemia but with more DKA events.
Week 24 outcomesDAPA 5 mg + INS (n=271)DAPA 10 mg + INS (n=270)Placebo + INS (n=272)HbA1c, % Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 8.45 (0.69) −0.34 (0.05) −0.37 (−0.49, −0.26) <0.0001. 8.39 (0.67) −0.39 (0.05) −0.42 (−0.53, −0.30) <0.0001. 8.40 (0.63) 0.03 (0.05) . .TDD, IU Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 59.09 (28.05) −8.73 (1.22) −10.78 (−13.73, −7.72) <0.0001. 59.28 (28.21) −9.(1.23) −11.(−14.04, −8.02) <0.0001. 56.45 (25.23) 2.29 (1.39) . .Body weight, kg Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 79.22 (17.21) −3.22 (0.27) −3.21 (−3.96, −2.45) <0.0001. 80.39 (18.51) −3.76 (0.27) −3.74 (−4.49, −2.99) <0.0001. 79.03 (19.05) −0.02 (0.28) . .24-h CGM glucose reading, mg/dL Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 192.67 (28.68) −6.46 (1.83) −15.66 (−20.26, −11.05) <0.0001. 191.53 (28.09) −10.54 (1.83) −19.74 (−24.34, −15.14) <0.0001. 190.89 (28.95) 9.20 (1.85) . .MAGE during 24-h CGM, mg/dL Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 169.35 (29.60) −10.17 (1.90) −9.85 (−14.66, −5.03) <0.0001. 171.02 (29.85) −9.68 (1.91) −9.36 (−14.16, −4.55) 0.0001. 168.38 (29.29) −0.33 (1.93) . .24-h interstitial glucose values within >70-≤180 mg/dL, % Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 43.50 (12.43) 5.92 (0.82) 9.02 (6.97, 11.06) <0.0001. 43.68 (11.83) 7.60 (0.82) 10.70 (8.66, 12.74) <0.0001. 43.53 (12.55) −3.10 (0.83) . .Safety data (patients with an event) ≥1 AE, n (%) ≥1 SAE, n (%) ≥1 related SAE, n (%) ≥1 event of hypoglycemia, n (%) ≥1 event of severe hypoglycemia, n (%) Definite DKA, n (%). 197 (72.7) 18 (6.6) 13 (4.8) 223 (82.3) 17 (6.3) 7 (2.6). 181 (67.0) 7 (2.6) 3 (1.1) 231 (85.6) 23 (8.5) 6 (2.2). 172 (63.2) 5 (1.8) 2 (0.7) 234 (86.0) 21 (7.7) 0
Disclosure
C. Mathieu: Research Support; Self; Novo Nordisk A/S. Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Sanofi. Research Support; Self; Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; Merck Sharp & Dohme Corp.. Advisory Panel; Self; Merck Sharp & Dohme Corp.. Research Support; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Novartis AG. Speaker's Bureau; Self; Novartis AG. Advisory Panel; Self; Novartis AG, Bristol-Myers Squibb Company. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; AstraZeneca, Pfizer Inc., Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Hanmi Pharmaceutical. Research Support; Self; Roche Diagnostics Corporation. Advisory Panel; Self; Roche Diagnostics Corporation. Research Support; Self; Medtronic. Advisory Panel; Self; Medtronic, MannKind Corporation. Research Support; Self; Intrexon. Advisory Panel; Self; Intrexon, Dianax, UCB, Inc.. Research Support; Self; Abbott. P. Dandona: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. P. Gillard: None. P.A. Senior: Consultant; Self; Abbott, AstraZeneca. Research Support; Self; AstraZeneca, Prometic Life Sciences Inc., Novo Nordisk Inc., Sanofi. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc., Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; AstraZeneca, Merck & Co., Inc., Abbott. Research Support; Self; Viacyte, Inc.. C. Hasslacher: None. E. Araki: Speaker's Bureau; Self; Astellas Pharma US, Inc., MSD K.K., Kowa Pharmaceuticals America, Inc., Sanofi, Novo Nordisk Inc.. Research Support; Self; Astellas Pharma US, Inc., MSD K.K., Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceuticals U.S.A., Inc., Daiichi Sankyo Company, Limited, Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Novo Nordisk Inc., Sanofi, Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama?Pharmaceutical Co. M. Lind: Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc.. Consultant; Self; Eli Lilly and Company. Advisory Panel; Self; MSD K.K.. Research Support; Self; Pfizer Inc.. Consultant; Self; Medtronic. S.C. Bain: Research Support; Self; Novo Nordisk Inc., AstraZeneca. S. Jabbour: None. N. Arya: Employee; Self; AstraZeneca. F.A. Thoren: Employee; Self; AstraZeneca. A. Langkilde: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. |
---|---|
AbstractList | The DEPICT-2 trial (NCT02460978) evaluated the efficacy and safety of dapagliflozin (DAPA) as add-on to adjustable insulin (INS) in patients (pts) with inadequately controlled T1D (A1c 7.5-10.5%) over 24 weeks. This phase 3 study randomized pts 1:1:1 to DAPA 5 mg (n=271), 10 mg (n=270) or placebo (PBO; n=272) plus INS. INS dose could be adjusted by the investigator according to self-monitored blood glucose readings, local guidance and individual circumstances. At Week 24, DAPA 5 and 10 mg significantly decreased A1c (0.37% and 0.42% reductions in the DAPA 5 mg and 10 mg groups respectively), total daily insulin dose (TDD), and body weight (Table). As measured by masked continuous glucose monitoring (CGM), mean interstitial glucose, mean amplitude of glucose excursion (MAGE) and mean percent of readings within target glycemic range (>70-≤180 mg/dL) vs. PBO were improved. There was an increase in pts who reduced their A1c by ≥0.5% without severe hypoglycemia (odds ratios [95% CI]: 2.71 [1.81, 4.06] and 3.07 [2.05, 4.60] for DAPA 5 and 10 mg respectively). Hypoglycemic events, including severe hypoglycemia were balanced between treatment groups. There were more adjudicated definite diabetic ketoacidosis (DKA) events on DAPA.
In conclusion, DAPA vs. PBO as add-on to INS in pts with T1D was well tolerated, improved glycemic control and decreased variability without increasing hypoglycemia but with more DKA events.
Week 24 outcomesDAPA 5 mg + INS (n=271)DAPA 10 mg + INS (n=270)Placebo + INS (n=272)HbA1c, % Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 8.45 (0.69) −0.34 (0.05) −0.37 (−0.49, −0.26) <0.0001. 8.39 (0.67) −0.39 (0.05) −0.42 (−0.53, −0.30) <0.0001. 8.40 (0.63) 0.03 (0.05) . .TDD, IU Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 59.09 (28.05) −8.73 (1.22) −10.78 (−13.73, −7.72) <0.0001. 59.28 (28.21) −9.(1.23) −11.(−14.04, −8.02) <0.0001. 56.45 (25.23) 2.29 (1.39) . .Body weight, kg Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 79.22 (17.21) −3.22 (0.27) −3.21 (−3.96, −2.45) <0.0001. 80.39 (18.51) −3.76 (0.27) −3.74 (−4.49, −2.99) <0.0001. 79.03 (19.05) −0.02 (0.28) . .24-h CGM glucose reading, mg/dL Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 192.67 (28.68) −6.46 (1.83) −15.66 (−20.26, −11.05) <0.0001. 191.53 (28.09) −10.54 (1.83) −19.74 (−24.34, −15.14) <0.0001. 190.89 (28.95) 9.20 (1.85) . .MAGE during 24-h CGM, mg/dL Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 169.35 (29.60) −10.17 (1.90) −9.85 (−14.66, −5.03) <0.0001. 171.02 (29.85) −9.68 (1.91) −9.36 (−14.16, −4.55) 0.0001. 168.38 (29.29) −0.33 (1.93) . .24-h interstitial glucose values within >70-≤180 mg/dL, % Mean (SD) at baseline Wk 24 adjusted mean change from baseline (SE) Difference vs PBO (95% CI) p value. 43.50 (12.43) 5.92 (0.82) 9.02 (6.97, 11.06) <0.0001. 43.68 (11.83) 7.60 (0.82) 10.70 (8.66, 12.74) <0.0001. 43.53 (12.55) −3.10 (0.83) . .Safety data (patients with an event) ≥1 AE, n (%) ≥1 SAE, n (%) ≥1 related SAE, n (%) ≥1 event of hypoglycemia, n (%) ≥1 event of severe hypoglycemia, n (%) Definite DKA, n (%). 197 (72.7) 18 (6.6) 13 (4.8) 223 (82.3) 17 (6.3) 7 (2.6). 181 (67.0) 7 (2.6) 3 (1.1) 231 (85.6) 23 (8.5) 6 (2.2). 172 (63.2) 5 (1.8) 2 (0.7) 234 (86.0) 21 (7.7) 0
Disclosure
C. Mathieu: Research Support; Self; Novo Nordisk A/S. Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Sanofi. Research Support; Self; Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; Merck Sharp & Dohme Corp.. Advisory Panel; Self; Merck Sharp & Dohme Corp.. Research Support; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Novartis AG. Speaker's Bureau; Self; Novartis AG. Advisory Panel; Self; Novartis AG, Bristol-Myers Squibb Company. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; AstraZeneca, Pfizer Inc., Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Hanmi Pharmaceutical. Research Support; Self; Roche Diagnostics Corporation. Advisory Panel; Self; Roche Diagnostics Corporation. Research Support; Self; Medtronic. Advisory Panel; Self; Medtronic, MannKind Corporation. Research Support; Self; Intrexon. Advisory Panel; Self; Intrexon, Dianax, UCB, Inc.. Research Support; Self; Abbott. P. Dandona: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. P. Gillard: None. P.A. Senior: Consultant; Self; Abbott, AstraZeneca. Research Support; Self; AstraZeneca, Prometic Life Sciences Inc., Novo Nordisk Inc., Sanofi. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc., Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; AstraZeneca, Merck & Co., Inc., Abbott. Research Support; Self; Viacyte, Inc.. C. Hasslacher: None. E. Araki: Speaker's Bureau; Self; Astellas Pharma US, Inc., MSD K.K., Kowa Pharmaceuticals America, Inc., Sanofi, Novo Nordisk Inc.. Research Support; Self; Astellas Pharma US, Inc., MSD K.K., Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceuticals U.S.A., Inc., Daiichi Sankyo Company, Limited, Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Novo Nordisk Inc., Sanofi, Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama?Pharmaceutical Co. M. Lind: Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc.. Consultant; Self; Eli Lilly and Company. Advisory Panel; Self; MSD K.K.. Research Support; Self; Pfizer Inc.. Consultant; Self; Medtronic. S.C. Bain: Research Support; Self; Novo Nordisk Inc., AstraZeneca. S. Jabbour: None. N. Arya: Employee; Self; AstraZeneca. F.A. Thoren: Employee; Self; AstraZeneca. A. Langkilde: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. |
Author | SENIOR, PETER A. HASSLACHER, CHRISTOPH BAIN, STEPHEN C. JABBOUR, SERGE ARAKI, EIICHI LANGKILDE, ANNA MARIA LIND, MARCUS THOREN, FREDRIK A. MATHIEU, CHANTAL DANDONA, PARESH ARYA, NIKI GILLARD, PIETER |
Author_xml | – sequence: 1 givenname: CHANTAL surname: MATHIEU fullname: MATHIEU, CHANTAL organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 2 givenname: PARESH surname: DANDONA fullname: DANDONA, PARESH organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 3 givenname: PIETER surname: GILLARD fullname: GILLARD, PIETER organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 4 givenname: PETER A. surname: SENIOR fullname: SENIOR, PETER A. organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 5 givenname: CHRISTOPH surname: HASSLACHER fullname: HASSLACHER, CHRISTOPH organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 6 givenname: EIICHI surname: ARAKI fullname: ARAKI, EIICHI organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 7 givenname: MARCUS surname: LIND fullname: LIND, MARCUS organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 8 givenname: STEPHEN C. surname: BAIN fullname: BAIN, STEPHEN C. organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 9 givenname: SERGE surname: JABBOUR fullname: JABBOUR, SERGE organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 10 givenname: NIKI surname: ARYA fullname: ARYA, NIKI organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 11 givenname: FREDRIK A. surname: THOREN fullname: THOREN, FREDRIK A. organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden – sequence: 12 givenname: ANNA MARIA surname: LANGKILDE fullname: LANGKILDE, ANNA MARIA organization: Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden |
BookMark | eNot0D1OwzAcBXALFYm2MHEB78jgjySOR5SWUqlSqzYDW-TYf4NRcEriCoWJQ3BCTkIr0HvS297wm6BRaAMgdM3oLRdC3tma5YQzQdbbMzRmSigiuHwaoTGljBMmlbxAk75_pZRmx4xRmDvnjTYD1sHinXYQB9w6PNN7_dx417SfPuBjNzp6CLHHHz6-4GXQFt4POkIz4KINsWubBiwuhz1ghmde1xCh__n6ns03y6IkHO_iwQ6X6Nzppoer_52i8mFeFo9ktV4si_sVMTLfklo5zlSeJdqqGhKZCC1ToxRNJTADUgueKM6hTtMkYcbwHBTPFWUiy2rJrJiim79b07V934Gr9p1_091QMVqdpKqTVHWUqtZb8Qvd2V5O |
CitedBy_id | crossref_primary_10_1507_endocrj_EJ21_0573 crossref_primary_10_2478_enr_2023_0018 crossref_primary_10_3389_fendo_2022_923376 crossref_primary_10_1111_1753_0407_12830 crossref_primary_10_1002_edm2_129 crossref_primary_10_1016_j_diabres_2020_108462 crossref_primary_10_3390_jcm10184078 crossref_primary_10_1007_s40200_023_01192_7 crossref_primary_10_58931_cdet_2023_1211 crossref_primary_10_2169_internalmedicine_9632_22 crossref_primary_10_2478_dine_2022_0009 |
ContentType | Journal Article |
CorporateAuthor | ON BEHALF OF THE DEPICT-2 INVESTIGATORS |
CorporateAuthor_xml | – name: ON BEHALF OF THE DEPICT-2 INVESTIGATORS |
DBID | AAYXX CITATION |
DOI | 10.2337/db18-213-OR |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X |
ExternalDocumentID | 10_2337_db18_213_OR |
GroupedDBID | --- .55 .XZ 08P 0R~ 18M 29F 2WC 354 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAQQT AAWTL AAYEP AAYOK AAYXX ABOCM ACGFO ACGOD ACPRK ADBBV AEGXH AENEX AERZD AFHIN AHMBA AIAGR AIZAD ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BES BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EJD EMOBN EX3 F5P FRP GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO K2M KQ8 L7B M5~ O5R O5S O9- OHH OK1 OVD P2P PCD Q2X RHF RHI RPM SJN SV3 TDI TEORI TR2 VVN W8F WH7 WOQ WOW X7M YFH YHG YOC ZY1 ~KM |
ID | FETCH-LOGICAL-c78R-b9f219864ad9be4743a75c99057e1ce7a324922eb55441cc28e928901366b71d3 |
ISSN | 0012-1797 |
IngestDate | Fri Aug 23 03:43:12 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c78R-b9f219864ad9be4743a75c99057e1ce7a324922eb55441cc28e928901366b71d3 |
ParticipantIDs | crossref_primary_10_2337_db18_213_OR |
PublicationCentury | 2000 |
PublicationDate | 2018-07-01 |
PublicationDateYYYYMMDD | 2018-07-01 |
PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationYear | 2018 |
SSID | ssj0006060 |
Score | 2.302684 |
Snippet | The DEPICT-2 trial (NCT02460978) evaluated the efficacy and safety of dapagliflozin (DAPA) as add-on to adjustable insulin (INS) in patients (pts) with... |
SourceID | crossref |
SourceType | Aggregation Database |
Title | Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study |
Volume | 67 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbpFkovpU_6Roe9BW0ry5bso1m7jcuuE1Iv5GYkWy4LwekjueypP6LQ_9df0pFkO94lh20hmCBbNsl81oxmvplB6JhKIX2l3hPacJ_4wg-IjKqQMA5vVxiYCmq22mfOZxf-p1Wwmkx-j1hLu606qa4O5pX8j1RhDORqsmT_QbLDTWEAvoN84QgShuOtZJya-g-mX7vlX8pGO3pFAgrwy_qyWW-uLi2RceGKp3aZbFkra_1tB0amKW3sqOprsDvNlnRKpx1H5kdPg_CTdJGdFsSznMNrUeBk5Li92dJn5GI4j4tZll5Yn-wszot4cDgncZ7M89h5AwELQ9zqY3Z2Fi8TeyJLi3SIR31O82xuyRsLMzyNT8Z-CxoOHNdhLaaeKY7q1K12y2_EIsI8sRqvz65dR4dD2-vUOk5LekgDeMzWEKgVPNCjjMyXe0XXB_dv6L-BlQj7ITO9NJNLmFzOl3fQXU9EgejdQJ2Kh12fy23qfoJL_DST342ePDJ1RjZL8RA96DYbOHbIeYQmun2M7p13dIonqO0BhAFA2AEIbxp8DUAYPj2AsAEQHgMI7wGEDYAwxT0q_vz81UMHW-g8RcWHtDidka4BB6lEuCQqakCfhdyXdaQ0vMdMiqAC8yUQmlZaSGbKTXpaBaaRXVV5oY5M3JoyzpWgNXuGjtpNq58jXIOZrLjn1zpsfF4pqbyGa84q2TShZPULdNz_VeVXV2alPCCOl7e77BW6v0fca3S0_b7Tb8B23Kq3Vo5_ASxKaRU |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Safety+of+Dapagliflozin+in+Patients+with+Inadequately+Controlled+Type+1+Diabetes%E2%80%94DEPICT-2+Study&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=MATHIEU%2C+CHANTAL&rft.au=DANDONA%2C+PARESH&rft.au=GILLARD%2C+PIETER&rft.au=SENIOR%2C+PETER+A.&rft.date=2018-07-01&rft.issn=0012-1797&rft.eissn=1939-327X&rft.volume=67&rft.issue=Supplement_1&rft_id=info:doi/10.2337%2Fdb18-213-OR&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db18_213_OR |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |